Devyser Diagnostics AB (STU:OL0)

Q3 2025 Devyser Diagnostics AB Earnings Call Transcript

Nov 5, 2025 / 08:00 AM GMT

Release Date Price: €9.94 (-8.30%)

Transcript

Key Points

Positve

Devyser Diagnostics AB (FRA:OL0) reported a record quarter with SEK 56 million in sales, representing a 20% growth in local currency.
The company achieved a gross margin of 75%, which is an improvement compared to the previous year's Q3.
Devyser Diagnostics AB (FRA:OL0) has successfully launched new products, including genomic blood typing and CFTR IVDR, enhancing its competitive position in Europe.
The company has a strong cash position of SEK 85 million, providing a solid financial foundation.
There is significant growth in the Americas, with an 87% increase in sales, driven by the lia Lab and US kit sales.

Negative

Distributor sales were down year-over-year, partly due to no major orders from Thermo Fisher in Q3.
The company's EBIT, although positive, is still just above zero, indicating a need for further improvement in profitability.
There is a delay in the Moldex evaluation for post-transplant tests in the US, as additional clinical data has been requested.
The gross margin was lower than expected due to fixed costs in COGS, impacting profitability.
The financial target of reaching 30% growth appears challenging, especially with delays in reimbursement processes.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

DVYSR.ST - Devyser Diagnostics AB
Q3 2025 Devyser Diagnostics AB Earnings Call
Nov 05, 2025 / 08:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and welcome to the Devisor Q3 2025 earnings call. I'm John Wallstrom. I'm the new CEO of Devisor since August 2025, and I would like to thank you everyone for joining our call today.

On the call today, we have, in addition to myself, also our CFO Sabina Berlin, and our CCO Ty Skipling.

I will start with a short summary of our quarterly result and then recap our recent activities that resulted in an improved efficiency overall for the organization. I will then give an update on the recent product launches and present some additional highlights from the quarter before handing over to Sabina for more detailed review of financial results in Q2, Q3, and then to Ties for an update on our recent commercial

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.